House subcommittee advances 10% budget increase for FDA in 2023
A House appropriations subcommittee advanced via voice vote a new spending bill for the FDA yesterday, offering $3.6 billion in discretionary funding (i.e. not user fees), which is a 10% increase from this year and a $3 million increase over the agency’s request.
Some of that increase, the committee said, or $64 million will be directed at the agency’s work on the opioid crisis, as CDC cited over 100,000 overdoses in 2021, as well as medical supply chain surveillance, drug safety oversight, and increasing and strengthening in-person inspections of drug manufacturers in India, specifically. The agency also will get $50 million in funds as part of the implementation of the 21st Century Cures Act.
“Because we recognize a dangerous gap and the need for more FDA inspection staff, we are ensuring the FDA has the resources and personnel to conduct inspections and thoroughly review infant formula application and manufacturing contracts,” Rosa DeLauro (D-CT), chair of the House appropriations committee, said yesterday. “This bill builds on the efforts by this Committee, through the House-passed supplemental appropriation and the oversight activities, to address this unacceptable and preventable crisis.”
The bill also provides $7 million in support of the Biden administration’s Cancer Moonshot program, according to written testimony of chair of the subcommittee Sanford Bishop (D-GA).
Speaking at the subcommittee hearing yesterday, Rep. Andy Harris (R-MD) called the 10% increase in FDA’s budget “overwhelming and unnecessary,” adding that, “rather than being held accountable, the FDA is being rewarded with more funding.”
The full House appropriations committee plans to meet next Thursday to discuss the FDA spending bill, which also could reach a floor vote next month.